AdVita: when discussing a project on the procurement of vital drugs, voices are raised
The cheating of votes began during the discussion on the federal portal of draft regulatory legal acts of a draft government decree, according to which a number of vital drugs will be purchased from a single domestic supplier if it organizes a full production cycle in the country. This is what Elena Gracheva, director of the Russian charitable foundation AdVita, says on Facebook.
She claims that the adoption of the document will negatively affect Russian patients – instead of the “extra third” rule, the “extra extra” rule will apply. “Doctors and patients will have no choice of drug. So far, the decree concerns not such a large number of items, but the trouble has begun. When the project first appeared, patient organizations opposed, ”she said.
According to the current rules, foreign drug manufacturers are not allowed to bid if two or more domestic suppliers take part in them, having a full production cycle of purchased drugs in Russia.
The document concerns such drugs as, for example, Abacavir, Zidovudine, Insulin Glargine, Protionamide, Thioureidoiminomethylpyridinium Perchlorate and others. There are 15 names in total.
Public discussion of the draft government decree should end on December 3. At the time of publication of the material, 761 people voted in support of the document, 954 voted against.
At the end of November, the Public Consumer Initiative (OPI) warned Roszdravnadzor about the seasonal shortage of drugs for COVID-19, flu and colds in pharmacies. According to the organization, they have not prepared for the seasonal increase in demand and a surge in morbidity, which is why drug prices are rising amid shortages. As noted, the situation is aggravated by the fact that 80 percent of pharmacies continue to freely sell prescription drugs.